compound III [PMID: 24080463]   Click here for help

GtoPdb Ligand ID: 8825

Compound class: Synthetic organic
Comment: Compound III is a survivin (BIRC5) inhibitor such as reported in patent US20110014192 A1 [2]. Compound III is a potential nordihydroguaiaretic acid (NDGA)-based anti-neoplastic agent [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 0
Rotatable bonds 29
Topological polar surface area 49.88
Molecular weight 670.54
XLogP 7.69
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCN(CCOc1cc(CCCCc2ccc(c(c2)OCCN(CC)CC)OCCN(CC)CC)ccc1OCCN(CC)CC)CC
Isomeric SMILES CCN(CCOc1cc(CCCCc2ccc(c(c2)OCCN(CC)CC)OCCN(CC)CC)ccc1OCCN(CC)CC)CC
InChI InChI=1S/C40H70N4O4/c1-9-41(10-2)25-29-45-37-23-21-35(33-39(37)47-31-27-43(13-5)14-6)19-17-18-20-36-22-24-38(46-30-26-42(11-3)12-4)40(34-36)48-32-28-44(15-7)16-8/h21-24,33-34H,9-20,25-32H2,1-8H3
InChI Key QROCYVPJPWZLIK-UHFFFAOYSA-N
References
1. Ho SS, Go ML. (2013)
Restraining the flexibility of the central linker in terameprocol results in constrained analogs with improved growth inhibitory activity.
Bioorg Med Chem Lett, 23 (22): 6127-33. [PMID:24080463]
2. Huang RC, Kimura K. (2011)
Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with metabolic modulators.
Patent number: US20110014192 A1. Assignee: The Johns Hopkins University. Priority date: 08/01/2008. Publication date: 20/01/2011.